EWTX
Edgewise Therapeutics, Inc. · Healthcare · Market cap $4.3B
Insiders sold $1.9M net in the last 90 days ·5 sellers, 0 buyers· 2 of 6 sales under Rule 10b5-1 plans· latest Form 4 filed Aug 14, 2026
Insider Buying
$199K
reported purchases (SEC code P)
Insider Selling
$19.5M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Oct 2, 2026
Donovan Joanne M.
Edgewise Therapeutics, Inc. (EWTX) has 17 SEC Form 4 filings (59 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Oct 2, 2026.
Inside the rolling window, 7 insiders at Edgewise Therapeutics, Inc. reported 1 open-market purchase totaling $199K and 14 open-market sales totaling $19.5M. The most active filer is CMO Donovan Joanne M. with 7 filings. Insiders have net sold $11.9M over the trailing 6 months. The most recent open-market filing is a sale of 6,522 shares by CMO Donovan Joanne M., dated Aug 12, 2026, worth $286K.
- Industry:Biotechnology
- CEO:Kevin Koch
- Employees:127
- HQ:Boulder, CO, US
- IPO:2021-03-26
| Source | |||||||
|---|---|---|---|---|---|---|---|
Donovan Joanne M.First in 3 months | CMO | Sale | 6,522 | $286K | Aug 14 | -10.2% | SEC ↗ |
Donovan Joanne M.First in 3 months | CMO | Sale | 2,919 | $127K | Aug 14 | -10.2% | SEC ↗ |
| Chief Scientific Officer | Sale | 5,901 | $258K | Aug 14 | -10.2% | SEC ↗ | |
MOORE JOHN RFirst filing | General Counsel | Sale | 5,016 | $220K | Aug 14 | -10.2% | SEC ↗ |
Derakhshan BehradFirst filing | Chief Business Officer | Sale | 5,100 | $223K | Aug 14 | — | SEC ↗ |
KOCH KEVINFirst filing | President and CEO | Sale | 17,971 | $785K | Aug 14 | — | SEC ↗ |
Russell Alan JFirst in 8 months | Chief Scientific Officer | Sale | 200,000 | $7.9M | Jul 2 | — | SEC ↗ |
| CMO | Sale | 5,230 | $164K | May 5 | — | SEC ↗ | |
| CMO | Sale | 50,000 | $1.9M | May 5 | — | SEC ↗ | |
| CMO | Sale | 28,662 | $926K | Apr 2 | — | SEC ↗ | |
| CMO | Sale | 21,338 | $685K | Mar 31 | — | SEC ↗ | |
Donovan Joanne M.First filing | CMO | Sale | 16,358 | $507K | Mar 30 | — | SEC ↗ |
Edris BadreddinFirst filing | Insider | Sale | 115,471 | $3.4M | Jan 23 | — | SEC ↗ |
Russell Alan JFirst filing | Chief Scientific Officer | Sale | 100,000 | $2.1M | Nov 13 | — | SEC ↗ |
Fox Jonathan CFirst filing | Director | Purchase | 10,700 | $199K | Nov 13 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does EWTX have?
Edgewise Therapeutics, Inc. (EWTX) has 17 SEC Form 4 filings (59 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Oct 2, 2026.
When was the most recent SEC Form 4 filing for EWTX?
The most recent Form 4 filing for EWTX on Tracefour is dated Oct 2, 2026.
Who is the most active insider at EWTX?
The most active SEC Form 4 filer at EWTX in the rolling window is CMO Donovan Joanne M., with 7 filings.
What is the net insider flow at EWTX over the last 6 months?
Over the trailing 180 days, insiders at EWTX have net sold $11.9M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at EWTX in the current window?
Inside the rolling window, insiders at EWTX bought $199K and sold $19.5M based on SEC Form 4 filings.
Can I get alerts for EWTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Edgewise Therapeutics, Inc. (EWTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Edgewise Therapeutics, Inc. is in the Healthcare sector.